SCHEMBL4318952

SCHEMBL4318952

NC(=O)C(=O)c1ccccn1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.75
CES1 P23141 1/20 0.75
LMNA P02545 4/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
NAPRT Q6XQN6 1/20 0.59
P4HTM Q9NXG6 1/20 0.59
ALDH1A1 P00352 2/20 0.57
KMT2A Q03164 2/20 0.53
GSK3B P49841 1/20 0.52
MAPK1 P28482 1/20 0.50
NPC1 O15118 5/20 0.49
RAB9A P51151 5/20 0.49
PKM P14618 4/20 0.49
CDK5 Q00535 2/20 0.49
CDK5R1 Q15078 2/20 0.49
MITF O75030 1/20 0.49
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29466797 0.86 CES2 (1.00) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL211487 0.86 CES2 (1.00) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL29466796 0.86 CES2 (1.00) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL30499331 0.83 CES2 (0.57) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL1382335 0.83 CES2 (0.57) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL1505348 0.82
SCHEMBL29976899 0.82 CES2 (0.82) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL61183 0.82
SCHEMBL4914089 0.82 CES2 (0.67) CES2CES1LMNAL3MBTL1NAPRT
SCHEMBL15180866 0.80 CES2 (0.78) CES2CES1LMNAL3MBTL1NAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2042502-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2009-04-01 EP disclosed
EP-1544199-B1 NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR JAPAN TOBACCO INC (JP) 2008-10-15 EP disclosed
US-20080161311-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. 2008-07-03 US disclosed
EP-1544199-A1 NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR JAPAN TOBACCO INC. (JP) 2005-06-22 EP disclosed
US-20050054645-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2005-03-10 US disclosed
US-6080738-A USEFUL AS CHYMASE INHIBITORS AND CAN BE USED FOR THE PROPHYLAXIS AND TREATMENT OF VARIOUS DISEASES CAUSED BY CHYMASE, SUCH AS THOSE CAUSED BY ANGIOTENSIN II YOSHITOMI PHARMACEUTICALS INDUSTRIES, LTD. (JP) 2000-06-27 US disclosed
EP-0940400-A1 NOVEL HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USES THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1999-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054645-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor NNMT, PNP, DNTT CES2 800/4885CES1 1050/4885LMNA 3234/4885
US-20080161311-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor DNTT, PNP, NNMT CES2 811/4885CES1 1430/4885LMNA 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.